Unknown

Dataset Information

0

Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity.

ABSTRACT: Antivector immunity has been recognized as a potential caveat of using virus-based vaccines. In the present study, an alphavirus-based replicon particle vaccine platform, which has demonstrated robust immunogenicity in animal models, was tested for effects of antivector immunity on immunogenicity against hemagglutinin of influenza virus as a target antigen and efficacy for protection against lethal challenge with the virus. Chimeric alphavirus-based replicon particles, comprising Venezuelan equine encephalitis virus nonstructural and Sindbis virus structural components, induced efficient protective antibody responses, which were not adversely influenced after multiple immunizations with the same vector expressing various antigens.

SUBMITTER: Uematsu Y 

PROVIDER: S-EPMC3393363 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity.

Uematsu Yasushi Y   Vajdy Michael M   Lian Ying Y   Perri Silvia S   Greer Catherine E CE   Legg Harold S HS   Galli Grazia G   Saletti Giulietta G   Otten Gillis R GR   Rappuoli Rino R   Barnett Susan W SW   Polo John M JM  

Clinical and vaccine immunology : CVI 20120523 7

Antivector immunity has been recognized as a potential caveat of using virus-based vaccines. In the present study, an alphavirus-based replicon particle vaccine platform, which has demonstrated robust immunogenicity in animal models, was tested for effects of antivector immunity on immunogenicity against hemagglutinin of influenza virus as a target antigen and efficacy for protection against lethal challenge with the virus. Chimeric alphavirus-based replicon particles, comprising Venezuelan equi  ...[more]

Similar Datasets

Unknown Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.
| S-EPMC2744093 | biostudies-literature
Unknown Development and characterization of promoterless helper RNAs for the production of alphavirus replicon particle.
| S-EPMC2888770 | biostudies-literature
Unknown Preexisting Immunity, More Than Aging, Influences Influenza Vaccine Responses.
| S-EPMC4567097 | biostudies-literature
Unknown An alphavirus replicon particle delivering prefusion-stabilized spike protein provides potent immunoprotection against SARS-CoV-2 Omicron variant.
| S-EPMC9747704 | biostudies-literature
Unknown Redirecting host preexisting influenza A virus immunity for cancer immunotherapy.
| S-EPMC8563826 | biostudies-literature
Unknown A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.
| S-EPMC3536361 | biostudies-literature
Unknown Mucosal and systemic adjuvant activity of alphavirus replicon particles.
| S-EPMC1383499 | biostudies-literature
Unknown Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.
| S-EPMC2937034 | biostudies-literature
Unknown Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.
| S-EPMC4406637 | biostudies-literature
Unknown An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector.
| S-EPMC228391 | biostudies-literature